Clinical trials: in Morocco
Hypofibrinogenemia, Congenital, Afibrinogenemia, Congenital
Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency
The aim of the study is to evaluate clinical pharmacology, efficacy and safety of FGTW in pediatric patients with congenital fibrinogen deficiency.
- Trial name
- NCT02094430
- Testing
- biological: human fibrinogen concentrate
- Where
- 4 sites in France, Lebanon and 2 more
- Volunteers
- 16 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Breast Cancer
A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
This single arm study will assess the safety and efficacy of a regimen of Avastin plus a taxane, with or without additional chemotherapy, as first-line treatment in patients with locally recurrent or metastatic breast cancer.
- Trial name
- NCT00448591
- Testing
- bevacizumab [Avastin], Taxane-based chemotherapy
- Where
- 457 sites in Argentina, Australia and 34 more
- Volunteers
- 2,296 people
- Sponsor
- Hoffmann-La Roche
Congenital Bleeding Disorder, Haemophilia A
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant human factor VII) in patients with haemophilia…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Trial name
- NCT01234545
- Testing
- activated recombinant human factor VII
- Where
- 5 sites in Algeria, Morocco and 3 more
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Acute Coronary Syndrome, Myocardial Infarction
An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome
The purpose of this study is to determine whether rivaroxaban in addition to standard care reduces the risk of the composite of cardiovascular death, myocardial infarction, or stroke in patients with a recent acute coronary…
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction, Myocardial Ischemia, Unstable Angina
- Trial name
- NCT00809965
- Testing
- Rivaroxaban 2.5 mg, Rivaroxaban 5 mg, Standard of care
- Where
- 556 sites in United States, Argentina and 41 more
- Volunteers
- 15,526 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Diabetes, Diabetes Mellitus, Type 1
An Observational Study on Efficacy and Safety in Subjects Using Levemir® for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes
This observational study is conducted in Africa. The aim of this observational study is to evaluate the efficacy and the incidence of serious adverse drug reactions while using insulin Levemir® under normal clinical practice…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00738153
- Testing
- insulin detemir
- Where
- Morocco
- Volunteers
- 798 people
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION)
This open label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to disease-modifying…
- Trial name
- NCT01610791
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 8 sites in Morocco
- Volunteers
- 121 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
This study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate.
- Trial name
- NCT00934648
- Testing
- rituximab [MabThera/Rituxan], methotrexate
- Where
- 5 sites in Morocco
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Hemophilia A
EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of…
- Trial name
- NCT00874926
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 17 sites in Bahrain, Bosnia and Herzegovina and 15 more
- Volunteers
- 405 people
- Sponsor
- Bayer
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer
H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer
This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.
- Trial name
- NCT01991340
- Where
- 19 sites in Algeria, Morocco
- Volunteers
- 657 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumors overexpress…
- Trial name
- NCT00558103
- Testing
- lapatinib, Pazopanib
- Where
- 126 sites in United States, Australia and 26 more
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Bronchitis, Chronic, Bronchial Diseases
Greatest International Antiinfective Trial With Avelox
The observation period for each patient covered an initial treatment period with Avelox® plus optional 2 long-term follow-up periods (6 and 12 months).For each patient, the physician documented data at any initial visit…
- Trial name
- GIANT (NCT00932802)
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 24 sites in Austria, Brazil and 22 more
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Anemia
An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia
This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta [Neorecormon] in patients with renal chronic anemia, who are on dialysis.
- Trial name
- NCT01105494
- Testing
- epoetin beta [NeoRecormon]
- Where
- Morocco
- Volunteers
- 6,000 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs
Primary Objective: To evaluate the efficacy of an intensive insulin regimen with insulin glargine and insulin glulisine in terms of change in Hemoglobin A1c (HbA1c) level from week 12 (visit 7) to week 24 (visit 10).
- Trial name
- CHANGING (NCT01203111)
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Algeria, Brazil and 8 more
- Volunteers
- 207 people
- Sponsor
- Sanofi
Hypertension
Treatment of Hypertension With Adalat® in Combination With Other Drugs
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.
- Trial name
- NCT01118286
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 11 sites in Bahrain, Egypt and 9 more
- Volunteers
- 4,497 people
- Sponsor
- Bayer
Chronic Bronchitis
PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis
Primary Objective: The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to…
- Trial name
- NCT00132938
- Testing
- telithromycin
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 5,660 people
- Sponsor
- Sanofi
Acute Coronary Syndromes
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
- Trial name
- NCT00214630
- Testing
- rosuvastatin calcium, atorvastatin
- Where
- 56 sites in United States, Costa Rica and 3 more
- Volunteers
- 825 people
- Sponsor
- AstraZeneca
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured…
- Trial name
- I-COMBINE (NCT00956644)
- Testing
- irbesartan/amlodipine, amlodipine
- Where
- 40 sites in Brazil, Chile and 7 more
- Volunteers
- 406 people
- Sponsor
- Sanofi
Hypertension
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy
Primary Objective: To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 300/5 mg is superior to that of irbesartan 300 mg monotherapy in lowering systolic blood pressure (SBP) as…
- Trial name
- I-ADD (NCT00957554)
- Testing
- irbesartan/amlodipine, irbesartan
- Where
- 38 sites in Brazil, Colombia and 6 more
- Volunteers
- 435 people
- Sponsor
- Sanofi